ALLMedicine™ Hepatorenal Syndrome Center

Mar 11th, 2023 - Portal hypertension (PH) is the most common complication of cirrhosis and represents the main driver of hepatic decompensation. The overarching goal of PH treatments in patients with compensated cirrhosis is to the reduce the risk of hepatic decom...

Mar 11th, 2023 - Terlipressin (Terlivaz) for hepatorenal syndrome.|2023||drug therapy,therapeutic use,

Mar 9th, 2023 - Medical Care Delivery of the fetus, regardless of gestational age, is the only treatment for acute fatty liver of pregnancy (AFLP) once the diagnosis has been made. Ending the pregnancy by delivery of the infant invariably results in resolution of...

Mar 4th, 2023 - Hepatorenal syndrome (HRS) is a diagnosis of exclusion defined as acute kidney injury (AKI) with cirrhosis and ascites, with serum creatinine unresponsive to standardized volume administration and diuretic withdrawal. Persistent intravascular hypo...

Feb 28th, 2023 - Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis.|2023|Sigal SH,Sanyal AJ,FredericK RT,Weinberg EM,Pappas SC,|

Sep 9th, 2022 - The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available published evidence and expert advice regarding the clinical management of patients with suspected acute kidney injury ...

May 5th, 2021 - Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.|2021|Biggins SW,Angeli P,Garcia-Tsao G,Ginès P,Ling S...

Feb 8th, 2023 - Patients with decompensated cirrhosis frequently develop various complications, be it related to salt and water retention, renal dysfunction, hepatic encephalopathy, portal hypertensive bleeds, or various infections. These lead to frequent hospita...

Feb 3rd, 2023 - Cirrhosis is a major cause of global health burden worldwide. Acute kidney injury (AKI) occurs in 20% of hospitalized patients with cirrhosis. Acute kidney injury is a relatively new definition of renal failure which takes into account the dynamic...

Feb 3rd, 2023 - The study will include 5 treatment arms including 1 Placebo Arm and 4 active drug arms. Participants will be randomly selected to 1 of 5 arms. Placebo OCE-205 at 8 micrograms per hour (µg/hr) OCE-205 at 15 micrograms per hour (µg/hr) OCE-205 at 30...

Jan 26th, 2023 - The decrease in systemic vascular resistance (SVR) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. Systemic vasodilatation is compensated by an increase in cardiac output (CO) in the i...

Jan 25th, 2023 - Hepatorenal syndrome-acute kidney injury (HRS-AKI), a potentially reversible renal failure, is a serious, rapidly progressing, often fatal, complication of decompensated cirrhosis. Terlipressin is a synthetic vasopressin analogue that acts as a sy...

Oct 31st, 2022 - In a subgroup of patients with hepatorenal syndrome type 1 (HRS) who received a liver transplant, terlipressin treatment appears to reduce the need for renal replacement therapy (RRT) through 12 months of follow-up, according to a study presented ...

Oct 28th, 2022 - In a subgroup of patients with hepatorenal syndrome type 1 (HRS) who received a liver transplant, terlipressin treatment appears to reduce the need for renal replacement therapy (RRT) through 12 months of follow-up, according to a study presented.

Oct 20th, 2022 - Acute kidney injury (AKI) in patients with cirrhosis is potentially preventable, and there are clear steps that can be taken to manage and reverse the condition, concludes a clinical practice update from the American Gastroenterological Associatio.

Sep 27th, 2022 - Acute kidney injury (AKI) in patients with cirrhosis is potentially preventable, and there are clear steps that can be taken to manage and reverse the condition, concludes a clinical practice update from the American Gastroenterological Associatio...

Sep 16th, 2022 - The US Food and Drug Administration (FDA) has approved terlipressin (Terlivaz), the first and only drug approved for patients with hepatorenal syndrome (HRS). HRS is characterized by progressive deterioration in kidney function in people with adva...